Literature DB >> 20393265

The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen.

Sebastiano Mercadante1, Patrizia Villari, Patrizia Ferrera, Salvatore Mangione, Alessandra Casuccio.   

Abstract

OBJECTIVES: To determine the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP).
METHODS: In 66 patients consecutive patients admitted to a pain relief and palliative care unit, the efficacy and safety of different opioids used in doses proportional to the basal opioid regimen for the management of breakthrough pain (BP) were assessed. The choice of the opioid to be administered as rescue medication was based on the characteristics of patients, clinical stability, compliance, preference, and so on. For each episode, nurses were instructed to routinely collect changes in pain intensity and emerging problems when pain became severe (T0), and to re-assess the patient 15 minutes after the opioid given as a rescue medication (T15).
RESULTS: Six hundred twenty four episodes of BP were recorded during admission. Intravenous morphine (IV-MO) and oral transmucosal fentanyl (OTFC) were most frequently administered. Of 503 events available, 427 episodes were defined as successfully treated, while 76 episodes required a further administration of opioids. Pain intensity significantly decreased at T15 in all the groups (P<0.001). In 97.2% and 90.7% of cases treated with IV-MO, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. In 99.2% and 97.6% patients receiving OTFC, BP events had a reduction in pain intensity of more than 33% and 50%, respectively. DISCUSSION: This survey suggests that doses of opioids for BP proportional to the basal opioid regimen, are very effective and safe in clinical practice, regardless the opioid and modality used.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393265     DOI: 10.1097/AJP.0b013e3181c4458a

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  7 in total

Review 1.  Idiopathic breakthrough pain: a new hypothesis.

Authors:  Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.

Authors:  Sebastiano Mercadante; Claudio Adile; Arturo Cuomo; Federica Aielli; Franco Marinangeli; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2016-10-15       Impact factor: 3.603

3.  The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Edoardo Arcuri
Journal:  Support Care Cancer       Date:  2010-09-30       Impact factor: 3.603

4.  Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit.

Authors:  Sebastiano Mercadante; Giovanna Prestia; Maurizio Ranieri; Antonello Giarratano; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-02-12       Impact factor: 3.603

5.  The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Federica Aielli; Lucilla Averna; Corrado Ficorella; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2013-04-07       Impact factor: 3.603

6.  Pain care for patients with epidermolysis bullosa: best care practice guidelines.

Authors:  Kenneth R Goldschneider; Julie Good; Emily Harrop; Christina Liossi; Anne Lynch-Jordan; Anna E Martinez; Lynne G Maxwell; Danette Stanko-Lopp
Journal:  BMC Med       Date:  2014-10-09       Impact factor: 8.775

7.  Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS).

Authors:  Sebastiano Mercadante; Paolo Marchetti; Arturo Cuomo; Augusto Caraceni; Rocco Domenico Mediati; Massimo Mammucari; Silvia Natoli; Marzia Lazzari; Mario Dauri; Mario Airoldi; Giuseppe Azzarello; Mauro Bandera; Livio Blasi; Giacomo Cartenì; Bruno Chiurazzi; Benedetta Veruska Pierpaola Costanzo; Daniela Degiovanni; Flavio Fusco; Vittorio Guardamagna; Vincenzo Iaffaioli; Simeone Liguori; Vito Lorusso; Sergio Mameli; Rodolfo Mattioli; Teresita Mazzei; Rita Maria Melotti; Valentino Menardo; Danilo Miotti; Stefano Moroso; Stefano De Santis; Remo Orsetti; Alfonso Papa; Sergio Ricci; Alessandro Fabrizio Sabato; Elvira Scelzi; Michele Sofia; Giuseppe Tonini; Federica Aielli; Alessandro Valle
Journal:  Adv Ther       Date:  2016-11-21       Impact factor: 3.845

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.